Medication info

Dubika Tablet 10/40mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›13.888mg / 1 tablet
Manufacturer / importer
Sama Pharmaceutical Co., Ltd.
Appearance
Brownish-red round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP x 2], 30 tablets/bottle
Approval status
Expired

MFDS item code 201500290 · Approved 2015.01.20

This product's status changed to Expired on 2025.01.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted before administering this medicine; however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ·Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ·Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ·Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Do not administer to the following patients.) ·Older adults: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In older adults, blood pressure should be monitored closely and more frequently.
Child dose
·Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Sama Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is used in patients with essential hypertension when blood pressure control is difficult with monotherapy. These medications effectively lower blood pressure, reduce the risk of cardiovascular diseases, and help improve patients' health. Therefore, they are used for the treatment of essential hypertension.

How to take

Adult dose

Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted before administering this medicine; however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ·Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ·Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ·Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Do not administer to the following patients.) ·Older adults: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In older adults, blood pressure should be monitored closely and more frequently.

Child dose

·Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second or third trimester of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. This drug should never be taken if there is an allergy to its main ingredients or similar substances, or if the person is pregnant or breastfeeding. Patients with severely impaired liver or kidney function, certain heart diseases or biliary obstruction, and specific genetic metabolic disorders should also avoid using this drug. In patients with insufficient body fluids or salts, hypotension may occur, so it is essential to closely monitor their condition during initial administration, and take appropriate action immediately if hypotension occurs. Due to its vasodilating effect, caution is required in patients with severe aortic stenosis, coronary artery disease, or congestive heart failure. Patients with impaired kidney function may have a risk of worsening kidney function, so regular monitoring is needed during the use of this drug. This medication may cause side effects such as dizziness, headache, hypotension, edema, and gastrointestinal disorders, so if any unusual symptoms arise, patients should consult a healthcare provider. This medication may interact with other drugs, so patients should inform their healthcare provider of any other medications they are taking, particularly when combined with blood pressure medications, diuretics, or potassium-sparing agents. Women who are pregnant or planning to become pregnant are recommended to use other blood pressure medications that have demonstrated safety instead of this one. Breastfeeding women should consider discontinuing breastfeeding or stopping the use of this medication due to its potential to be transferred through breast milk. It is advisable not to use this medication in pediatric patients under 18 years of age as safety and efficacy have not been established. In elderly patients, lower doses should be started considering reduced kidney and liver function, and their condition should be closely monitored. In case of overdose, severe hypotension and vascular dilation may occur, so immediate medical attention is necessary.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • postural hypotension
  • drowsiness
  • paresthesia
  • sensory loss
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • weakness
  • facial swelling
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gums bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute kidney failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • rhabdomyolysis
  • acute kidney failure
  • elevated serum creatinine
  • hair loss
  • itching
  • urticaria
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is essential to maintain the storage temperature between 1 to 30 degrees Celsius to ensure the effectiveness of the medication is retained and it can be used safely.

Appearance and packaging

Appearance

Brownish-red round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP x 2], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.